Thermo Fisher Scientific Inc. (TMO)

NYSE · Waltham, Massachusetts, USA · Founded 1956 · CEO Marc Casper

Valuation summary

$444.69 fair value versus $688.75 in the market, a difference of -35.4%. Rated Sell.

Fair value per share$444.69
Current share price$688.75
Upside / downside-35.4%
Bear case$267.06
Bull case$699.03
Discount rate (WACC)8.9%
Terminal growth2.60%
Market capitalisation$255B
EV / Sales6.2x

About Thermo Fisher Scientific Inc.

Formed by the 2006 merger of Thermo Electron, founded in 1956, and Fisher Scientific. Marc Casper has been CEO since 2009 and has made the company the largest life sciences supplier in the world through relentless acquisition. Thermo Fisher sells the instruments, reagents, consumables and contract manufacturing services that pharmaceutical companies, hospitals and academic labs depend on. It profits from drug development activity itself, regardless of which drugs succeed.

Investment case

  • Sells to the entire industry rather than betting on individual drugs — a picks-and-shovels position in biopharma.
  • Consumables and reagents are recurring revenue tied to installed instruments.
  • An exceptional acquisition track record, with a repeatable integration playbook.

Key risks

  • Pharmaceutical R&D budgets and biotech funding drive demand, and both have been under pressure.
  • China represents a meaningful share of revenue and has been weak.
  • The post-pandemic normalisation in lab spending has taken longer than expected.

Recent developments

Revenue by segment

Laboratory Products & Biopharma Services55%
Life Sciences Solutions17%
Analytical Instruments17%
Specialty Diagnostics11%

Five-year forecast

RevenueFree cash flow
Year 1$51.2B$9.6B
Year 2$55.4B$10.3B
Year 3$60.0B$11.1B
Year 4$65.0B$11.9B
Year 5$70.4B$12.8B

What the street says

Held in high regard as a compounder, and sentiment has improved: the shares rose about 25% in the three months to early October 2026. Deutsche Bank and JPMorgan both turned more positive, citing end-market improvement, a path to high-single-digit growth by 2028 and demand from US pharmaceutical manufacturing reshoring.

Comparable companies: AZN · JNJ · ABT · MDT · ABBV · AMGN · SYK · SNY

Open the interactive model, price chart and sensitivity grid →